TP53 and ovarian carcinoma: To assess the resistance of ovarian cancer cells to the platinum-based drug (cisplatin), we obtained information from two ovarian cancer cell lines: TOV21G, characterized by wild type of p53 (p53-WT) and OVCAR8, characterized by mutant p53 (p53-mut) (Figure 1A).